Amphetamine Addiction Clinical Trial
Official title:
The Intervention of Group Therapy: Music in Mood Problems of Female Amphetamine Use Disorder
Verified date | November 2018 |
Source | Shanghai Mental Health Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The group music therapy will be used to treat female amphetamine-type stimulant (ATS) addiction
Status | Completed |
Enrollment | 40 |
Est. completion date | September 30, 2018 |
Est. primary completion date | August 30, 2018 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | N/A and older |
Eligibility |
Inclusion Criteria: - In accordance with the Diagnostic and Statistical Manual of Mental Disorders-5 (DSM-5) for methamphetamine (MA) use disorder - Junior high school degree or above - Normal vision and hearing - Have emotional problem Exclusion Criteria: - Other substance abuse or dependence in recent a years (except nicotine) - Mental impairment, Intelligence Quotient (IQ) < 70 - Mental disorders - Physical disease |
Country | Name | City | State |
---|---|---|---|
China | Shanghai Women's Compulsory Isolation Detoxification Center | Shanghai |
Lead Sponsor | Collaborator |
---|---|
Shanghai Mental Health Center |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change from Baseline Depression status assessed by Self-rating Depression Scale (SDS) at 4 months. | evaluate all participants' depression status by Self-rating Depression Scale (SDS) | Baseline, 2 months,4 months, and 7months | |
Secondary | Anxiety status assessed by Self-rating Anxiety Scale (SAS) | evaluate all participants' anxiety status by Self-rating Anxiety Scale (SAS) | Baseline, 2 months,4 months, and 7months | |
Secondary | Change from Baseline Craving for ATS assessed by Visual Analog Scales (VAS) | evaluate all participants' craving for ATS by Visual Analog Scales (VAS) | Baseline, 2 months,4 months, and 7months | |
Secondary | Empathy ability assessed by Interpersonal Reactivity Index-C(IRI-C) | evaluate all participants' Empathy ability by Interpersonal Reactivity Index-C(IRI-C) | Baseline, 2 months,4 months, and 7months | |
Secondary | Motivation for treatment assessed by Stages of Change Readiness and Treatment Eagerness Scale(SOCRATES) | evaluate all participants' motivation for treatment assessed by Stages of Change Readiness and Treatment Eagerness Scale(SOCRATES) | Baseline, 2 months,4 months, and 7months | |
Secondary | Change from Baseline emotional status assessed by emotional STROOP paradigm | evaluate all participants' emotional status by emotional STROOP paradigm | Baseline, 2 months,4 months, and 7months | |
Secondary | Sleep status assessed by Pittsburgh Sleep Quality Index(PSQI) | evaluate all participants' sleep status by Pittsburgh Sleep Quality Index(PSQI) | Baseline, 2 months,4 months, and 7months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT05535101 -
Non-invasive Brain Stimulation in Patients With Methamphetamine Use Disorder
|
N/A | |
Not yet recruiting |
NCT02836756 -
Cannabidiol as a New Intervention for Amphetamine Dependence
|
Phase 2 | |
Completed |
NCT03318081 -
The Application of Cognitive Rehabilitation Therapy for Amphetamine-type Stimulants Addiction
|
N/A | |
Withdrawn |
NCT02952196 -
Cannabioids as a New Intervention for Amphetamine Dependence
|
Phase 2 | |
Completed |
NCT02285556 -
The Diagnostic Assessment and Intervention Study of Amphetamine Type Stimulus
|
N/A | |
Completed |
NCT02713815 -
Novel Intervention for Amphetamine-type Stimulants Addiction
|
N/A | |
Completed |
NCT00713479 -
An Assessment of the Safety of Varenicline in Methamphetamine-dependent Volunteers
|
Phase 1 | |
Completed |
NCT04993300 -
Repetitive Transcranial Magnetic Stimulation in Amphetamine Addiction
|
N/A | |
Completed |
NCT02950376 -
The Novel Addiction Assessment Study in Synthetic Drugs Addiction
|
||
Recruiting |
NCT04531384 -
Robot-Assisted Intelligent Rehabilitation Treatment for Methamphetamine Use Disorders.
|
N/A | |
Recruiting |
NCT04687566 -
Dextromethorphan, Memantine Monotherapy, or Combined Use of Dextromethorphan and Memantine in Amphetamine Addiction
|
Phase 2/Phase 3 |